跳至主要内容
临床试验/NCT05931601
NCT05931601招募中3 期

Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled Trial

Odense University Hospital6 个研究点 分布在 2 个国家目标入组 320 人开始时间: 2023年12月8日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
招募中
入组人数
320
试验地点
6
主要终点
The primary outcome is the proportion of patients achieving either SBP >100 mmHg or MAP > 65 mmHg or a target blood pressure set by the treating physician at 90 (±15) minutes after inclusion.

研究概览

简要总结

The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid only therapy in patients with hypotensive and shock in the Danish and Swedish Emergency Departments (ED).

The main questions it aims to answer are:

If early initiated noradrenaline in non-bleeding hypotensive patients presenting in the ED can

  • Improve time to shock control.
  • Reduce the need for ICU admittance.
  • Decrease mortality.

Participants will be included by the clinical staff and treated urgently with either noradrenaline or usual treatment during their Emergency Department stay.

After completion of the treatment in the Emergency Department, patient data will be extracted from the bed-side measurements, electronic health records and national registers.

Patients will be contacted by the research staff 1 year after study inclusion to answer brief questions about their daily physical function and ability to care for themselves.

Researchers will compare with patients receiving fluid therapy only, as this is the usual standard of care in Danish and Swedish Emergency Departments.

详细描述

Please refer to the full protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years of age
  • Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as:
  • SBP < 100mmHg or MAP < 65 mmHg combined with lactate > 2.0 mmol/L,
  • Physician defined blood pressure for the individual patient combined with a lactate > 2.0 mmol/L
  • Either SBP < 100mmHg or MAP < 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician.
  • Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival.
  • Clinical Frailty Score (CFS) of ≤
  • If CFS is ≥5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion.

排除标准

  • Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician.
  • Fertile women (<60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding.
  • Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant.
  • Known allergy to noradrenaline.

研究组 & 干预措施

Intervention

Experimental

Peripheral noradrenaline will be infused at rates of 0.05-0.15 mcg/kg/min for up to 24 hours after randomization in the ED until shock control is achieved.

If shock control cannot be achieved, patients will be transferred to the ICU for further treatment of their condition but without further trial intervention.

Weaning of intervention will be completed during the 24 hours, and if possible, terminated.

If termination of treatment is not achievable within 24 hours, participants will be transferred to the ICU.

干预措施: Noradrenaline (Drug)

结局指标

主要结局

The primary outcome is the proportion of patients achieving either SBP >100 mmHg or MAP > 65 mmHg or a target blood pressure set by the treating physician at 90 (±15) minutes after inclusion.

时间窗: At 90 minutes

Bed-side assessment during treatment and registered in the case report form.

次要结局

  • Number of intensive care unit (ICU) free days alive within 30 days(At 30 days)
  • Time without shock within 24 hours(At 24 hours)
  • 30-day all-cause mortality(At 30 days)
  • In-hospital all-cause mortality(At hospital discharge, an average of 30 days efter inclusion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lasse Paludan Bentsen, MD

Coordinating and Principal Investigator

Odense University Hospital

研究点 (6)

Loading locations...

相似试验